The therapy is also approved for treating advanced gastric cancer and relapsed or metastatic cervical cancer after ...

HCG Manavata Cancer Centre has successfully performed its first Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC) ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...

A clinical trial using engineered immune cells to hunt cancer cells has reported impressive results for solid tumours, a type ...

In the United States, approximately 55% of resected gallbladder cancer (GBC) patients undergo oncologic surgery without ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

Phase 3 trial shows trastuzumab deruxtecan extends survival by over three months in advanced HER2-positive gastric cancer and ...

advanced, CLDN18.2-positive gastric or gastroesophageal junction cancer," the authors write. The study, led by Changsong Qi, MD, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumour ...

Cancer patients given experimental treatment that programmes the body to attack rogue cells live 40 per cent longer, major ...